Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin to reduce infection in decompensated cirrhosis (UK multicentre trial)
2016-002628-96Phase 4Unknown
- Sponsor
- Imperial College London
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Cirrhosis and bacterial disease comparing Rifaximin (Targaxan) with Placebo (2 arms). Primary endpoint: Infection rate during hospital admission. Status: unknown.
02
Drugs
rifaximin alpha
03
Conditions
Cirrhosisbacterial disease
Beyond the preview
Go deeper on 2016-002628-96.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002628-96.